

- Dai X, Theobard R, Cheng H, Xing M, Zhang J. Fusion genes: A promising tool combating against cancer. *Biochim Biophys Acta Rev Cancer*. 2018;1869(2):149–160.
- Delogu GL, Matos MJ. Coumarins as promising scaffold for the treatment of age-related diseases—An overview of the last five years. *Curr Top Med Chem*. 2017;17(29):3173–3189.
- Dorval T, Chanrion B, Cattin ME, Stephan JP. Filling the drug discovery gap: Is high-content screening the missing link? *Curr Opin Pharmacol*. 2018;42:40–45.
- Farmakiotis D, Kontoyiannis DP. Epidemiology of antifungal resistance in human pathogenic yeasts: Current viewpoint and practical recommendations for management. *Int J Antimicrob Agents*. 2017;50(3):318–324.
- Gothai S, Muniandy K, Gnanaraj C, Ibrahim IAA, Shahzad N, Al-Ghamdi SS, Ayoub N et al. Pharmacological insights into antioxidants against colorectal cancer: A detailed review of the possible mechanisms. *Biomed Pharmacother*. 2018;107:1514–1522.
- Haasen D, Schopfer U, Antczak C, Guy C, Fuchs F, Selzer P. How phenotypic screening influenced drug discovery: Lessons from five years of practice. *Assay Drug Dev Technol*. 2017;15(6):239–246.
- Hollingsworth SA, Dror RO. Molecular dynamics simulation for all. *Neuron*. 2018;99(6):1129–1143.
- Järbe TUC, Raghav JG. Tripping with synthetic cannabinoids (“Spice”): Anecdotal and experimental observations in animals and man. *Curr Top Behav Neurosci*. 2017;32:263–281.
- Khan H, Rengasamy KRR, Pervaiz A, Nabavi SM, Atanasov AG, Kamal MA. Plant-derived mPGES-1 inhibitors or suppressors: A new emerging trend in the search for small molecules to combat inflammation. *Eur J Med Chem*. 2018;153:2–28.
- Laubach JP, Paba Prada CE, Richardson PG, Longo DL. Daratumumab, elotuzumab, and the development of therapeutic monoclonal antibodies in multiple myeloma. *Clin Pharmacol Ther*. 2017;101(1):81–88.
- Law BYK, Wu AG, Wang MJ, Zhu YZ. Chinese medicine: A hope for neurodegenerative diseases? *J Alzheimers Dis*. 2017;60(s1):S151–S160.
- Li J, Qiao Y, Wu Z. Nanosystem trends in drug delivery using quality-by-design concept. *J Control Release*. 2017;256:9–18.
- Li W, Pang IH, Pacheco MTF, Tian H. Ligandomics: A paradigm shift in biological drug discovery. *Drug Discov Today*. 2018;23(3):636–643.
- Meyer RJ. Commentary on R&D trends away from general medicine/cardiovascular drugs: Can the FDA help reverse the trend? *Clin Pharmacol Ther*. 2017;102(2):186–188.
- Mukherjee PK, Harwansh RK, Bahadur S, Banerjee S, Kar A, Chanda J, Biswas S, Ahmmed SM, Katiyar CK. Development of ayurveda—Tradition to trend. *J Ethnopharmacol*. 2017;197:10–24.
- Nguyen MA, Flanagan T, Brewster M, Kesiosoglou F, Beato S, Biewenga J, Crison J et al. A survey on IVIVC/IVIVR development in the pharmaceutical industry—Past experience and current perspectives. *Eur J Pharm Sci*. 2017;102:1–13.
- Polini A, Mercato LLD, Barra A, Zhang YS, Calabi F, Gigli G. Towards the development of human immune-system-on-a-chip platforms. *Drug Discov Today*. 2018.
- Rameshrad M, Razavi BM, Hosseinzadeh H. Saffron and its derivatives, crocin, crocetin and safranal: A patent review. *Expert Opin Ther Pat*. 2018;28(2):147–165.
- Ran X, Gestwicki JE. Inhibitors of protein-protein interactions (PPIs): An analysis of scaffold choices and buried surface area. *Curr Opin Chem Biol*. 2018;44:75–86.
- Rashidi MR, Soltani S. An overview of aldehyde oxidase: an enzyme of emerging importance in novel drug discovery. *Expert Opin Drug Discov*. 2017;12(3):305–316.